NCT00515567 Explanted Lung Tissues With Pulmonary Fibrosis
| NCT ID | NCT00515567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Pulmonary Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2006-02 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2006-02 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
Eligibility Criteria
Inclusion Criteria: * all patients awaiting lung transplant Exclusion Criteria: * all who will not give consent
Contact & Investigator
Nickolai Dulin, MD
✉ ndulin@bsd.uchicago.eduNickolai Dulin, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT00515567 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00515567 currently recruiting?
Yes, NCT00515567 is actively recruiting participants. Contact the research team at ndulin@bsd.uchicago.edu for enrollment information.
Where is the NCT00515567 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT00515567 clinical trial?
NCT00515567 is sponsored by University of Chicago. The principal investigator is Nickolai Dulin, MD at University of Chicago. The trial plans to enroll 90 participants.